Hunter C Smith Rhythm Pharmaceuticals, Inc. (RYTM) insider trading activity

Hunter C Smith is Chief Financial Officer of RHYTHM PHARMACEUTICALS, INC.. Currently has a direct ownership of 116,915 shares of RYTM, which is worth approximately $11.6 Million. The most recent transaction as insider was on Jul 09, 2025, when has been sold 42,120 shares (Common Stock) at a price of $78.68 per share, resulting in proceeds of $3,314,001. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 117K

6.36% 3M change

19.38% 12M change

Total Value Held $11.6 Million

Hunter C Smith Transaction History

Date	Transaction	Value	Shares Traded	Shares Held
Jul 09 2025	SELL Open market or private sale	$3,314,001 $78.68 p/Share	42,120 Reduced 26.48%	116,915 Common Stock
Jul 09 2025	BUY Exercise of conversion of derivative security	$289,785 $6.88 p/Share	42,120 Added 20.94%	159,035 Common Stock
Jul 07 2025	BUY Exercise of conversion of derivative security	$48,063 $6.88 p/Share	6,986 Added 5.64%	116,915 Common Stock
May 30 2025	SELL Open market or private sale	$1,432,782 $61.23 p/Share	23,400 Reduced 17.55%	109,929 Common Stock
May 30 2025	BUY Exercise of conversion of derivative security	$160,992 $6.88 p/Share	23,400 Added 14.93%	133,329 Common Stock
Feb 19 2025	SELL Open market or private sale	$126,742 $57.22 p/Share	2,215 Reduced 1.98%	109,929 Common Stock
Feb 16 2025	BUY Exercise of conversion of derivative security	-	6,600 Added 5.56%	112,144 Common Stock
Feb 12 2025	SELL Open market or private sale	$42,288 $56.31 p/Share	751 Reduced 0.71%	105,544 Common Stock
Feb 11 2025	SELL Open market or private sale	$74,545 $57.52 p/Share	1,296 Reduced 1.2%	106,295 Common Stock
Feb 11 2025	BUY Exercise of conversion of derivative security	-	2,343 Added 2.13%	107,591 Common Stock
Feb 09 2025	BUY Exercise of conversion of derivative security	-	4,062 Added 3.72%	105,248 Common Stock
Feb 04 2025	SELL Open market or private sale	$99,723 $59.43 p/Share	1,678 Reduced 1.63%	101,186 Common Stock
Feb 01 2025	BUY Exercise of conversion of derivative security	-	4,925 Added 4.57%	102,864 Common Stock
Mar 19 2024	SELL Open market or private sale	$608,498 $39.22 p/Share	15,515 Reduced 13.68%	97,939 Common Stock
Feb 16 2024	BUY Grant, award, or other acquisition	-	33,750 Added 22.93%	113,454 Common Stock
Feb 13 2024	SELL Open market or private sale	$35,322 $49.82 p/Share	709 Reduced 0.88%	79,704 Common Stock
Feb 12 2024	SELL Open market or private sale	$62,118 $51.38 p/Share	1,209 Reduced 1.48%	80,413 Common Stock
Feb 11 2024	BUY Exercise of conversion of derivative security	-	2,344 Added 2.79%	81,622 Common Stock
Feb 09 2024	BUY Exercise of conversion of derivative security	-	4,063 Added 4.88%	79,278 Common Stock
Feb 01 2024	SELL Open market or private sale	$72,816 $45.06 p/Share	1,616 Reduced 2.1%	75,215 Common Stock
Feb 01 2024	BUY Exercise of conversion of derivative security	-	4,925 Added 6.02%	76,831 Common Stock
Dec 29 2023	BUY Exercise of conversion of derivative security	$72,240 $6.88 p/Share	10,500 Added 12.74%	71,906 Common Stock
Dec 06 2023	SELL Open market or private sale	$800,000 $40.0 p/Share	20,000 Reduced 24.57%	61,406 Common Stock
Dec 06 2023	BUY Exercise of conversion of derivative security	$137,600 $6.88 p/Share	20,000 Added 19.72%	81,406 Common Stock
Dec 05 2023	SELL Open market or private sale	$246,331 $35.06 p/Share	7,026 Reduced 10.27%	61,406 Common Stock

Also insider at

AGLE

Aeglea BioTherapeutics, Inc. Healthcare

Director

HCS

Hunter C Smith

Chief Financial Officer

Boston, MA

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells RYTM shares.

Notify only if

Value

Insider Trading

Get notified when an Rhythm Pharmaceuticals, Inc. insider buys or sells RYTM shares.

Notify only if

Operation

Value

Type

News

Receive news related to RHYTHM PHARMACEUTICALS, INC.

Track Activities on RYTM

Account